All News

Some patients with aplastic anemia treated with CK0801 achieved durable transfusion independence lasting over 3 years.

Pharmacy and physician were defendants.

Pharmacy technicians have a pivotal opportunity to advance professionally by proactively demonstrating leadership, offering solutions, and clearly communicating their value to health care leaders.

Zahra Mahmoudjafari, PharmD, BCOP, FHOPA, shared insight from the HOPA Annual Meeting 2025.

The safety profile of diazepam nasal spray among pediatric patients was consistent with older patients, supporting its use in this age group.

Arefa Bacchus, PharmD, shared key insights about the use of POMP therapy in patients with acute lymphoblastic leukemia (ALL).

A palliative care pharmacist highlights a spectrum of clinical opportunities for patients, caregivers, and clinicians when rounding at the bedside.

Monica Sawiris, PharmD, said there were noticeable differences in toxicities between each regimen.

The designation was supported based on data from the randomized, double-blind, active-controlled phase 3 interchangeability study.

Erin Lexner, PharmD, BCPS, discussed her team’s experience transitioning to outpatient BEAM from inpatient CBV.

Shelby Quinn, PharmD, BCOP shares insights about treatment using osimertinib in early lines.

SOC emphasizes adaptability and individual professional judgment without compromising quality, as individuals are held to the standard and expertise of their practice area.

Strategies for rescuing PTPRD function in diseased livers could provide potential therapeutic options, according to the study authors.

Data indicate potential benefits and risks with nutritional supplement use, highlighting the need for pharmacist counseling.

The high acceptance rates of these interventions demonstrate the key role in optimizing patient care that clinical oncology pharmacists with access to medical records play.

Current treatment strategies are aimed at reducing hematocrit and symptom burden through phlebotomy, aspirin, and cytoreductive agents, while emerging therapies offer promise for better disease control and quality of life.

Imlunestrant is an investigational, brain-penetrating, oral selective degrader of estrogen receptor.

The new indication expands administration methods for the combination of efgartigimod alfa and hyaluronidase-qvfc, which are already approved for the treatment of some immune-related conditions.

Promoting weight management prior to pregnancy and in early life may yield stronger cardiovascular and maternal health.

Expert provides a comprehensive overview of drug diversion prevention in pharmacy settings.

Pharmacists share key insights about the use of ADCs for treatment of breast cancer.

There are no clearly defined, widely accepted clinical pharmacist metrics.

Collecting, analyzing, and interpreting data are pharmacist skills.

Pharmacists should educate patients about their treatment regimen and potential adverse effects.

Christine Barrett, PharmD, BCOP, shares insights, challenges, and advice for oncology pharmacists navigating neoadjuvant therapy.

Scott A. Soefje, PharmD, MBA, BCOP, explained how the expanding use of the FDA’s 505(b)(2) drug approval pathway is creating operational and reimbursement challenges for oncology infusion centers.

Jessica Davis, PharmD, BCOP highlights the role of pharmacy technicians in ambulatory oncology clinic settings.

Rather than turning to vitamin K supplements, individuals should incorporate more vegetables into their diets.